Xconomy was named Synthorx as one of the most exciting life science startups in San Diego because of our unique drug discovery platform. In 2014, Synthorx was founded based on the synthetic biology breakthrough from the Romesberg lab at The Scripps Research Institute, who created two novel DNA bases, X and Y, that can be recognized and replicated in vivo.
We use our expanded genetic alphabet technology to develop new protein therapeutics and to improve the safety, efficacy and potency of existing drugs. Synthorx has an internal drug development pipeline and is partnering with pharmaceutical companies to discover and develop new protein therapeutics for unmet medical needs including pain, metabolic disorders, infectious diseases and cancer.
Click here for the full article.